Actinium Pharmaceuticals and Aveo Oncology have signed a research partnership for developing and analysing an ErbB3 (HER3)-targeting antibody radio-conjugate (ARC) for solid tumour treatment.
Actinium’s Antibody Warhead Enabling (AWE) technology platform and its broad radiotherapy capabilities will be leveraged to conjugate ErbB3 targeted antibodies of Aveo with Actinium-225 (Ac-225).
This conjugation will lead to the formation of a new Ac-225 ErbB3 targeted radiotherapy.
Actinium-225 is a potent alpha-emitting radioisotope.
The ErbB3 targeting antibodies of Aveo are intended to hinder ligand-dependent and ligand-independent ErbB3 signalling
A receptor, ErbB3 is also called HER3 and is overexpressed in several solid tumours, including head and neck, colorectal, breast, ovarian, gastric, melanoma, prostate and bladder cancers.
It also showed activity in various tumour models in preclinical research.
Actinium chairman and CEO Sandesh Seth said: “We believe ErbB3 is a validated and differentiated target that is aptly suited for radio-conjugate development
Leave a Reply